DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,799,337 B2 Levin (45) Date of Patent: *Sep

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,799,337 B2 Levin (45) Date of Patent: *Sep US0077993.37B2 (12) United States Patent (10) Patent No.: US 7,799,337 B2 Levin (45) Date of Patent: *Sep. 21, 2010 (54) METHOD FOR DIRECTED INTRANASAL (56) References Cited ADMINISTRATION OF ACOMPOSITION U.S. PATENT DOCUMENTS (76) Inventor: Bruce H. Levin, 125 Broome St., 3,105,854. A 10/1963 Druey Merion, PA (US) 19066 Continued (*) Notice: Subject to any disclaimer, the term of this ( ) patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 382 days. BE 1 OO9851. A 10, 1997 inplent is Subject to a terminal dis- (Continued) OTHER PUBLICATIONS (21) Appl. No.: 10/218,138 Goodman and Gilman's The Pharmacological Basis of Therapeutics, (22) Filed: Aug. 12, 2002 tenth edition, McGraw Hill publishing, pp. 278-281.* (65) Prior Publication Data (Continued) Primary Examiner—San-ming Hui US 2003/O133877 A1 Jul 17, 2003 y 9. ll. If, (74) Attorney, Agent, or Firm Panitch Schwarze Belisario & Related U.S. Application Data Nadel LLP (63) Continuation-in-part of application No. 09/737,302, (57) ABSTRACT filed on Dec. 15, 2000, now abandoned, and a continu riggerial o o E.2. E. Methods, kits, apparatus, and compositions for inhibiting a ation-in-part of application No. 09/118,615.filed on cerebral neurovascular disorder, a muscular headache, or Jul.17, 1998, now Pat No. 6.432.986, cerebral inflammation in a human patient are provided. The r s - 1s methods comprise intranasally administering to the patient a (60) Provisional application No. 60/117,398, filed on Jan. pharmaceutical composition comprising a local anesthetic, i. d'E' pysis, application S. Of . and preferably a long-acting local anesthetic ingredient. A Soo 1 6.hisdon Jul psya E. composition useful for practicing the methods of the inven cation No. 60,072,845, filed on ". 1998 ER: tion is described which comprises at least one local anesthetic sional application No. 60,084.559 filed on May 6 in a pharmaceutically acceptable carrier, wherein the compo 1998. sa- a-- s s sition is formulated for intranasal delivery. Cerebral neu rovascular disorders include migraine and cluster headache. (51) Int. Cl. Muscular headaches include tension headaches and muscle A6DF 3/00 (2006.01) contraction headaches. A kit comprising the composition and A61N L/30 (2006.01) an intranasal applicator and a method of systemically deliv A6M I/00 (2006.01) ering a pharmaceutically active agent to an animal are also (52) U.S. Cl. ........................... 424/434; 604/19, 604/27; included in the invention. Apparatus for directed intranasal 604/30 administration of the compositions of the invention and for (58) Field of Classification Search ................. 424/434, performing the methods of the invention are also described. 424/401; 600/120, 144 See application file for complete search history. 23 Claims, 8 Drawing Sheets US 7,799,337 B2 Page 2 U.S. PATENT DOCUMENTS EP O 754 453 A1 1, 1997 EP O 755 678 A1 1, 1997 3,260,258 A 7, 1966 Berman GB 2315 673. A 2, 1998 3,568,678 A 3/1971 Pourquier WO WO95/10276 4f1995 3,862,321 A 1/1975 Adams et al. WO WO95/21821 8, 1995 3,867.946 A 2/1975 Huddy WO WO96,32109 10, 1996 3,914,283 A 10, 1975 Okamoto et al. WO WO 97.15548 5, 1997 3,925,469 A 12/1975 Adams et al. WO WO97, 18855 * 5, 1997 3,988.475 A 10/1976 Manghisi WO WO97,23467 7/1997 4,073.917 A 2/1978 Sandberg et al. WO WO 97/38675 10, 1997 4,117,160 A 9, 1978 Molnar et al. WO WO98, 15275 A 4f1998 4,138.492. A 2f1979 Noverola WO WO 98,38998 9, 1998 4,147,804 A 4, 1979 Diamond et al. WO WO99,32103 7, 1999 4,147,805 A 4, 1979 Morrow 4,163,789 A 8, 1979 Mauri OTHER PUBLICATIONS 4,217,349 A 8, 1980 Katsube et al. 4,280,493 A 7, 1981 Council Frey, William H., II, Ph.D., “Bypassing the Blood-Brain Barrier to 4,298,603 A 11/1981 Chang et al. Deliver Therapeutic Agents to the Brain and Spinal Cord.” Jul.-Aug. 4,352,820 A 10, 1982 Scurlocket al. 2002 Issue of Drug Delivery Technology (Applicant received copy 4,379,161 A 4, 1983 Thominet et al. Jul. 15, 2002). 4,397,845. A 8, 1983 Allen 1996, Med. Sci. Bull. 19(4): 1. 4.495,174 A 1, 1985 Allcock et al. Aberg, 1972, Acta Pharmacol. Toxicol. 3 1:273-286. 4,551.453 A 11, 1985 Marsili Anthony, 1992, Clin. Neurol. NeuroSurg.94:297-301. 4,562,060 A 12/1985 Broberg et al. APS, 1978, Br. J. Clin. Pharmac. 6:63-68. 4,585,866 A 4, 1986 Fozard Ariéns, 1991, Eur, J. Clin. Pharmacol. 41(2):89-93. 4,622,219 A 1 1/1986 Haynes Ariéns, 1990, Pharmaceutisch Weekblad 125:(22)552-554. 4,632,940 A 12/1986 Chiarino et al. Ariéns, 1990, Schweiz Med. Wochenschr, 120(5) 131-134. 4,636,387 A 1, 1987 Allcock et al. Barth, 1984, Pain S269 (abstract - XP-002068058). 4,695,576 A 9, 1987 af Ekenstam et al. Barré, 1982, Headache 22(2):69-73. 4,727,145 A 2, 1988 Press Burm, et al., 1994, Br. J. Clin. Pharmacol. 38:125-129. 4,755,174 A 7, 1988 Milewski et al. Butterworth, et al., 1993, Anesthesiology 79(1):88-95. 4,819,619 A 4, 1989 Augustine et al. Caputi, 1997, Headache 37(3):174-179. 4,821,715 A 4/1989 Downing Clark, et al., 1991, J. Chromatog. 553:383-390. 4,833,149 A 5/1989 Press Clarkson, et al., 1985, Anesthesiology 62:396-405. 4,871,745 A 10, 1989 PreSS Courtney, et al., 1988, Biochim. Biophys. Acta 939:163-166. 4,886,493 A 12, 1989 Yee ............................ 604,516 Dejong, et al., 1981, Reg. Anesth. 6:99-103. 4.937,078 A 6, 1990 Mezei et al. Denson, et al., 1992, Reg. Anesth. 17:311-316. 5,008,289 A 4, 1991 Bernstein Du Pen, et al., 1992, Pain 49:293-300. 5,085,868 A 2f1992 Mattsson et al. Fozzard, et al., 1985, Card. Electrophys. Arrhythmias 51-57. 5,227,165 A 7, 1993 Domb et al. Gristwood, et al., 1994, Exp. Opin. Invest. Drugs 3(11): 1209-1212. 5,234,957 A 8, 1993 Mantelle Honerjäger, 1986, Basic Res. Cardiol. 81 (Suppl.):33-37. 5,332,576 A 7, 1994. Mantelle Kuhnert, et al., 1981, Fed. Proc. 40(31):684 Drug Disposition, 5,360,805. A 1 1/1994 Asket al. Abstract 2599. 5,387,587 A 2f1995 Hausler et al. Lee-Son; et al., 1992, Anesthesiology 77:324-335. 5,420,151 A 5/1995 Hammarberg et al. Luduena, et al., 1970, Heterocyclic Compounds 73(5), Abstract 5,428,006 A 6/1995 Bechgaard et al. 25314a. 5,527,293 A 6, 1996 Zamierowski Luduena, et al., 1972, Arch. Int. Pharmacodyn. 200:359-369. 5,578,315 A 11/1996 Chien et al. Maciewicz, 1988, Clin. J. Pain 4:11-16. 5,624,898 A 4/1997 Frey, II Mather, 1991, Br. J. Anaesth. 67:239-246. 5,639,772 A 6/1997 Hammarberg et al. Mazoit, 1993, Anesth Analg 77:477-482. 5,656,657 A 8/1997 Hammarberg et al. Moskowitz, 1993, Neurology 43 (Suppl. 3): S16-S20. 5,660,837 A 8/1997 Lundquist Niesel, 1990, Reg. Anaesth. 13(3):54-56 (abstract only). 5,667,799 A 9, 1997 Caldwell Reiz, et al., 1986, Br. J. Anaesth. 58:736-746. 5,676,635 A 10, 1997 Levin Reynolds, 1995, Int. J. Obst. Anesth. 4:93-108. 5,676,691 A 10, 1997 Friedman Robbins, 1995, Headache 35: 83-84. 5,676.955 A 10, 1997 Ansmann et al. Rowland, et al., 1995, Clin. Pharmacokin. 83-88. 5,726, 187 A 3, 1998 Gaster Rutten, et al., 1992, J. Pharm. Pharmacol. 44:355-358. 5,756.520 A 5, 1998 Asket al. Rutten, et al., 1991, Br. J. Anaesth, 67:247-256. 5,840,755 A 11/1998 Liedtke Rutten, et al., 1993, Chirality 5(7):485-491. 5,858.410 A 1, 1999 Muller Schlepper, 1989, European Heart Journal 10(Suppl):73-80. 5,939.425. A 8, 1999 Caruso Strichartz, 1988, Neural Physiology and Local Anesthetic Action pp. 5,964,223. A 10, 1999 Baran 25-45 in: Neural Blockade in Clinical Anesthesia and Management of 6,019,994 A 2/2000 Evetts Pain, J.B. Lippincott. 6,110,937 A 8/2000 Loughhead Testa, et al., 1990, Chirality 2:129-133. 6,180,603 B1 1/2001 Frey, II Vanhoutte, et al., 1991, Br. J. Pharmacol. 103: 1275-1281. 6,407,061 B1 6/2002 Frey, II Valenzuela, et al., 1994, Biophys. J. 66: A205 (abstract only 6.432,986 B2 8, 2002 Levin Tu-Pos383). 6,444,205 B2 9, 2002 Dinsmore et al. Wahedi, et al., 1990, Reg. Anaesth. 13(3):66-72 (abstract only). 6,491,940 B1 12/2002 Levin ......................... 424/434 Wang, et al., 1992, J. Gen. Physiol. 100: 1003-1020. Diamond, 1996, Jama 276(19): 1553. FOREIGN PATENT DOCUMENTS Gherardini, 1995, Acta Anaesthesiol. Scand. 39(6):765-768. Lane, 1996, J. Am. Med. Assoc. 276(19): 1553. EP T54060 10, 1995 Sachs, 1996, J. Am. Med. Assoc.276(19): 1553-1554. US 7,799,337 B2 Page 3 Scott, et al., 1989, Anesth. Analg. 69(5):563-569 (abstract only). Goadsby et al., 1987, Am J.
Load more

Recommended publications
  • Appendix 1 Table of Contents
    @ECHA EUROPEAN CHEMICALS AGENCY Appendix 1 Table of Contents: Supplementary Table C:Substances on Annex II of the Cosmetic Products Regulation ... 1 Supplementary Table D: Substances proposed to be restricted due their use restriction in CPR Annex IV column 9..,,.. 119 Supplementary Table E: Substances allowed in tattoo inks subject to the conditions specified in CPR Annex IV columns h and i ......r29 Annankatu 18. P.O. Box 400, FI-00121 Helsinki, Finland I Tel. +358 9 686180 | Fax +358 9 68618210 | echa.europa.eu ANNEX XV RESTRICTION REPORT - SUBSTANCES IN TATTOO INKS AND PERMANENT MAKE UP Su lemen Table C:Substances on Annex II of the Cosmetic Products Re ulationl Substance EC# cAs # Substance EC# cAs # R T T T A- s c R I T Name Name e b b b II s M 7 c I s I I I #4 5 6 D 9 2 1 2 3 a 3 3 3 N-(s- Chlorobenzoxa zol-2- 35783- vl)acetamide 57-4 1 (2- Acetoxyethyl)t rimethylammo (2- nium acetoxyethyl hydroxide )trimethyla 200- (Acetylcholine) 200- mmonium 124-9 5 1-84-3 and its salts t2a-9 51-84-3 2 Deanol Deanol 222- 3342- aceglumate 222- 3342- aceqlumate 085-5 61-8 (INN) 085-5 61-8 3 Spironolacto 200- Spironolactone 200- ne 133-6 52-O1-7 rINN) 133-6 52-0L-7 4 14-(4- Hydroxy-3- iodophenoxy)- 3,5- diiodophenylla cetic acid (Tiratricol 200- (INN)) and its 200- Tiratricol 086- 1 5r-24-7 salts 086- 1 5l-24-7 5 Methotrexat 200- Methotrexate 200- e 413-8 59-05-2 (INN) 413-8 59-05-2 6 Aminocaproic Aminocaproi 200- acid (INN) and 200- c acid 469-3 60-32-2 its salts 469-3 60-32-2 7 Cinchophen (rNN), its salts, derivatives and salts of 205- 132-60- these 205- 132-60- Cinchophen 067-r 5 derivatives 067-l 5 Thyropropic acid (INN) and its salts 5L-26-3 9 Trichloroacet 200- Trichloroacetic 200- ic acid 927-2 75-03-9 acid 927-2 76-03-9 l0 Aconitum napellus L.
    [Show full text]
  • Europæisk Patentskrift
    (19) DANMARK (1°) DK/EP 2968225 T3 (12) Oversættelse af europæisk patentskrift Patent- og Varemærkestyrelsen (51) lnt.CI.: A 61 K 31/137 (2006.01) A 61 K 9/00 (2006.01) A 61 K 31/245 (2006.01) A 61 K 31/445 (2006.01) A 61 K 31/519 (2006.01) A 61 K 31/52 (2006.01) A 61 P 43/00 (2006.01) (45) Oversættelsen bekendtgjort den: 2019-05-27 (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: 2019-02-20 (86) Europæisk ansøgning nr.: 14719486.4 (86) Europæisk indleveringsdag: 2014-03-17 (87) Den europæiske ansøgnings publiceringsdag: 2016-01-20 (86) International ansøgning nr.: US2014030372 (87) Internationalt publikationsnr.: WO2014145580 (30) Prioritet: 2013-03-15 US 201361789054 P (84) Designerede stater: AL AT BE BG CH CY CZ DE DK EE ES Fl FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (73) Patenthaver: The Children's Medical Center Corporation, 55 Shattuck Street, Boston, Massachusetts 02115, USA (72) Opfinder: BERDE, Charles, 14 Doran Road, Bookline, MA 02146, USA KOHANE, Daniel S., 119 Willard Street, Newton, MA 02461, USA (74) Fuldmægtig i Danmark: AWA Denmark A/S, Strandgade 56,1401 København K, Danmark (54) Benævnelse: NEOSAXITOXINKOMBINATIONSFORMULERINGER TIL FORLÆNGET LOKALANÆSTESI (56) Fremdragne publikationer: WO-A2-98/51290 ALBERTO J. RODRIGUEZ-NAVARRO ET AL: "Potentiation of Local Anesthetic Activity of Neosaxitoxin with Bupivacaine or Epinephrine: Development of a Long-Acting Pain Blocker", NEUROTOXICITY RESEARCH, vol. 16, no. 4, 28 July 2009 (2009-07-28), pages 408-415, XP055122925, ISSN: 1029-8428, DOI: 10.1007/s12640-009- 9092-3 cited in the application Anonymous: "NCT01786655 on 2013_02_11: ClinicalTrials.gov Archive",, 11 February 2013 (2013-02-11), XP055122935, Retrieved from the Internet: URL:http://clinicaltrials.gov/archive/NCTO 1786655/2013_02_11 [retrieved on 2014-06-12] CHARLES B.
    [Show full text]
  • Journal of Pharmacology and Experimental Therapeutics
    Journal of Pharmacology and Experimental Therapeutics Molecular Determinants of Ligand Selectivity for the Human Multidrug And Toxin Extrusion Proteins, MATE1 and MATE-2K Bethzaida Astorga, Sean Ekins, Mark Morales and Stephen H Wright Department of Physiology, University of Arizona, Tucson, AZ 85724, USA (B.A., M.M., and S.H.W.) Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina NC 27526, USA (S.E.) Supplemental Table 1. Compounds selected by the common features pharmacophore after searching a database of 2690 FDA approved compounds (www.collaborativedrug.com). FitValue Common Name Indication 3.93897 PYRIMETHAMINE Antimalarial 3.3167 naloxone Antidote Naloxone Hydrochloride 3.27622 DEXMEDETOMIDINE Anxiolytic 3.2407 Chlordantoin Antifungal 3.1776 NALORPHINE Antidote Nalorphine Hydrochloride 3.15108 Perfosfamide Antineoplastic 3.11759 Cinchonidine Sulfate Antimalarial Cinchonidine 3.10352 Cinchonine Sulfate Antimalarial Cinchonine 3.07469 METHOHEXITAL Anesthetic 3.06799 PROGUANIL Antimalarial PROGUANIL HYDROCHLORIDE 100MG 3.05018 TOPIRAMATE Anticonvulsant 3.04366 MIDODRINE Antihypotensive Midodrine Hydrochloride 2.98558 Chlorbetamide Antiamebic 2.98463 TRIMETHOPRIM Antibiotic Antibacterial 2.98457 ZILEUTON Antiinflammatory 2.94205 AMINOMETRADINE Diuretic 2.89284 SCOPOLAMINE Antispasmodic ScopolamineHydrobromide 2.88791 ARTICAINE Anesthetic 2.84534 RITODRINE Tocolytic 2.82357 MITOBRONITOL Antineoplastic Mitolactol 2.81033 LORAZEPAM Anxiolytic 2.74943 ETHOHEXADIOL Insecticide 2.64902 METHOXAMINE Antihypotensive Methoxamine
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Proxymetacaine Hydrochloride Ropivacaine Hydrochloride
    1870 Local Anaesthetics Preparations pore: Alcaine; Switz.: Alcaine; Turk.: Alcaine; Opticaine; USA: Ak-Taine; Alcaine; Ocu-Caine; Ophthetic; Parcaine; Venez.: Alcaine; Oftaine†; Poen- (details are given in Part 3) caina. Proprietary Preparations CH3 Multi-ingredient: Spain: Detraine. O Multi-ingredient: Canad.: Fluoracaine†; USA: Fluoracaine; Fluorocaine. N CH3 O Quinisocaine Hydrochloride (BANM, rINNM) H3C Propipocaine (rINN) O Chinisocainum Hydrochloride; Dimethisoquin Hydrochloride Propipocaína; Propipocaïne; Propipocainum; Propoxypipero- (USAN); Dimethisoquinium Chloride; Hidrocloruro de quinisocaí- NH2 caine. 3-Piperidino-4′-propoxypropiophenone. na; Quinisocaïne, Chlorhydrate de; Quinisocaini Hydrochlori- (proxymetacaine) dum. 2-(3-Butyl-1-isoquinolyloxy)-NN-dimethylethylamine hy- Пропипокаин drochloride. C17H25NO2 = 275.4. Хинизокаина Гидрохлорид CAS — 3670-68-6. NOTE. PROX is a code approved by the BP 2008 for use on single unit doses of eye drops containing proxymetacaine hydrochlo- C17H24N2O,HCl = 308.8. ride where the individual container may be too small to bear all CAS — 86-80-6 (quinisocaine); 2773-92-4 (quinisocaine the appropriate labelling information. PROXFLN is a similar hydrochloride). O code approved for eye drops containing proxymetacaine hydro- ATC — D04AB05. chloride and fluorescein sodium. ATC Vet — QD04AB05. N Pharmacopoeias. In Br. and US. BP 2008 (Proxymetacaine Hydrochloride). A white or almost H3C CH3 white, odourless or almost odourless, crystalline powder. Soluble O in water and in chloroform; very soluble in dehydrated alcohol; N practically insoluble in ether. A 1% solution in water has a pH of O CH Profile 5.7 to 6.4. Protect from light. 3 Propipocaine is a local anaesthetic (p.1850) that has been used USP 31 (Proparacaine Hydrochloride). A white to off-white, or for surface anaesthesia.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Ep 1931310 B1
    (19) & (11) EP 1 931 310 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/12 (2006.01) A61K 9/06 (2006.01) 06.06.2012 Bulletin 2012/23 A61K 9/70 (2006.01) A61K 47/32 (2006.01) A61K 47/24 (2006.01) A61K 47/10 (2006.01) (21) Application number: 06779420.6 (86) International application number: (22) Date of filing: 14.09.2006 PCT/GB2006/003408 (87) International publication number: WO 2007/031753 (22.03.2007 Gazette 2007/12) (54) Monophasic film-forming composition for topical administration Monophasische filmbildende Zusammensetzung zum topischen Auftrag Composition monophase formant un film pour l’administration à voie topique (84) Designated Contracting States: • JONES, Stuart, Allen AT BE BG CH CY CZ DE DK EE ES FI FR GB GR London SE3 0XA (GB) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (74) Representative: Lord, Hilton David Marks & Clerk LLP (30) Priority: 14.09.2005 GB 0518769 90 Long Acre London (43) Date of publication of application: WC2E 9RA (GB) 18.06.2008 Bulletin 2008/25 (56) References cited: (73) Proprietor: Medpharm Limited WO-A2-01/43722 US-A- 4 752 466 Charlbury, US-A- 4 863 721 US-A1- 2004 184 994 Oxfordshire OX7 3RR (GB) US-A1- 2004 213 744 (72) Inventors: • BROWN, Marc, Barry Hertfordshire WD19 4QQ (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Pdf; Chi 2015 DPP Air in Cars.Pdf; Dodson 2014 DPP Dust CA.Pdf; Kasper-Sonnenberg 2014 Phth Metabolites.Pdf; EU Cosmetics Regs 2009.Pdf
    Bouge, Cathy (ECY) From: Nancy Uding <[email protected]> Sent: Friday, January 13, 2017 10:24 AM To: Steward, Kara (ECY) Cc: Erika Schreder Subject: Comments re. 2016 CSPA Rule Update - DPP Attachments: DPP 131-18-0 exposure.pdf; Chi 2015 DPP air in cars.pdf; Dodson 2014 DPP dust CA.pdf; Kasper-Sonnenberg 2014 phth metabolites.pdf; EU Cosmetics Regs 2009.pdf Please accept these comments from Toxic-Free Future concerning the exposure potential of DPP for consideration during the 2016 CSPA Rule update. Regards, Nancy Uding -- Nancy Uding Grants & Research Specialist Toxic-Free Future 206-632-1545 ext.123 http://toxicfreefuture.org 1 JES-00888; No of Pages 9 JOURNAL OF ENVIRONMENTAL SCIENCES XX (2016) XXX– XXX Available online at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/jes Determination of 15 phthalate esters in air by gas-phase and particle-phase simultaneous sampling Chenchen Chi1, Meng Xia1, Chen Zhou1, Xueqing Wang1,2, Mili Weng1,3, Xueyou Shen1,4,⁎ 1. College of Environmental & Resource Sciences, Zhejiang University, Hangzhou 310058, China 2. Zhejiang National Radiation Environmental Technology Co., Ltd., Hangzhou 310011, China 3. School of Environmental and Resource Sciences, Zhejiang Agriculture and Forestry University, Hangzhou 310058, China 4. Zhejiang Provincial Key Laboratory of Organic Pollution Process and Control, Hangzhou 310058, China ARTICLE INFO ABSTRACT Article history: Based on previous research, the sampling and analysis methods for phthalate esters (PAEs) Received 24 December 2015 were improved by increasing the sampling flow of indoor air from 1 to 4 L/min, shortening the Revised 14 January 2016 sampling duration from 8 to 2 hr.
    [Show full text]
  • 8–16–01 Vol. 66 No. 159 Thursday Aug. 16, 2001 Pages 42929
    8–16–01 Thursday Vol. 66 No. 159 Aug. 16, 2001 Pages 42929–43064 VerDate 11-MAY-2000 19:13 Aug 15, 2001 Jkt 194001 PO 00000 Frm 00001 Fmt 4710 Sfmt 4710 E:\FR\FM\16AUWS.LOC pfrm11 PsN: 16AUWS 1 II Federal Register / Vol. 66, No. 159 / Thursday, August 16, 2001 The FEDERAL REGISTER is published daily, Monday through SUBSCRIPTIONS AND COPIES Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, PUBLIC Washington, DC 20408, under the Federal Register Act (44 U.S.C. Subscriptions: Ch. 15) and the regulations of the Administrative Committee of Paper or fiche 202–512–1800 the Federal Register (1 CFR Ch. I). The Superintendent of Assistance with public subscriptions 512–1806 Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition. General online information 202–512–1530; 1–888–293–6498 Single copies/back copies: The Federal Register provides a uniform system for making available to the public regulations and legal notices issued by Paper or fiche 512–1800 Federal agencies. These include Presidential proclamations and Assistance with public single copies 512–1803 Executive Orders, Federal agency documents having general FEDERAL AGENCIES applicability and legal effect, documents required to be published Subscriptions: by act of Congress, and other Federal agency documents of public interest. Paper or fiche 523–5243 Assistance with Federal agency subscriptions 523–5243 Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing.
    [Show full text]
  • WO 2016/140629 Al 9 September 2016 (09.09.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/140629 Al 9 September 2016 (09.09.2016) P O P C T (51) International Patent Classification: (74) Agent: BULUT, Pinar; FarmaPatent Limited Sirketi, A61K 36/28 (2006.01) A61P 17/02 (2006.01) GMK Bulvari No:42/5, Maltepe, 06440 Ankara (TR). A61K 36/38 (2006.01) A61P 23/00 (2006.01) (81) Designated States (unless otherwise indicated, for every A61K 31/167 (2006.01) kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, PCT/TR20 15/000088 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 5 March 2015 (05.03.2015) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (25) Filing Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicant: PHARMACTFVE ILAC SANAYI VE Tl- TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. CARET A. S. [TR/TR]; Mahmutbey Mah. Dilmenler Cad., (84) Designated States (unless otherwise indicated, for every Aslanoba Plaza No: 19 K:3, Bagcilar/istanbul (TR).
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]